In the field of CVDs, the potential to develop treatments that specifically inhibit p130Cas could influence the management of myocardial hypertrophy and remodeling, PAH, and atherosclerosis, offering new hope for patients suffering from these debilitating diseases (Fig. 3). This evidence concerns the gene BCAR1 and pulmonary arterial hypertension.